This randomized double-blind controlled trial enrolled 104 morbidly obese patients to compare neuromuscular blockade reversal agents. The intervention group received sugammadex at 2 mg/kg, while the comparator group received neostigmine (50 μg/kg) plus atropine (20 μg/kg). The primary outcome was change in deep breathing diaphragmatic excursion (ΔDE) from baseline at T2.
Main results showed significantly smaller reductions in diaphragmatic excursion with sugammadex compared to neostigmine+atropine at T2 (0.05 cm vs. 0.28 cm, p<0.001). Secondary outcomes also favored sugammadex: ΔDE at T1, ΔTF at T1, and ΔTF at T2 all differed significantly between groups (p≤0.001). The postoperative oxygenation index was higher in the sugammadex group (p=0.004), and the incidence of postoperative pulmonary complications was lower (p=0.007).
Safety and tolerability data were not reported in the available evidence. Key limitations include the specific population of morbidly obese patients, which may limit generalizability to other patient groups. The study design was robust with double-blinding, but longer-term outcomes and detailed safety profiles were not assessed.
For clinical practice, these findings suggest sugammadex may offer respiratory advantages in morbidly obese patients undergoing surgery, particularly regarding diaphragmatic function and pulmonary complication rates. However, clinicians should consider the limited population scope and await further research confirming these benefits in diverse patient groups before changing practice patterns.
View Original Abstract ↓
PURPOSE: Compared with neostigmine, sugammadex promotes faster neuromuscular recovery, but its impact on diaphragmatic function and respiratory recovery in the morbidly obese cohort, and the mechanism underlying its reduction of postoperative pulmonary complications remain unclear. This study aims to compare the effects of sugammadex and neostigmine on diaphragmatic function and respiratory recovery in morbidly obese patients after surgery, and to investigate the role of diaphragmatic function in the reduction of sugammadex-associated postoperative pulmonary complications.
PATIENTS AND METHODS: For neuromuscular blockade reversal, 104 morbidly obese patients with moderate neuromuscular block (train-of-four count = 2, ratio <0.9) were randomly assigned to receive either neostigmine (50 μg kg-1+atropine 20 μg kg-1, n=51) or sugammadex (2 mg kg-1, n=53). Measurements of diaphragmatic excursion (DE) and thickening fraction (TF) were taken during deep and quiet breathing at T0 (baseline), T1 (10 min), and T2 (30 min) after extubation. The primary outcome measure was the change in deep breathing diaphragmatic excursion (ΔDE) from baseline at T2. The secondary outcome measures included ΔDE, ΔDE, and ΔTF at T1; ΔDE and ΔTF at T2; postoperative oxygenation index; number of respiratory reminders; and the frequency of postoperative pulmonary complications.
RESULTS: At T2, the ΔDE was smaller in the sugammadex group compared with the neostigmine group (0.05 cm vs. 0.28 cm; < 0.001). At T1, the ΔDE, ΔDE, and ΔTF all differed significantly between groups, as did the ΔTF at T2 (all ≤ 0.001). The sugammadex group also demonstrated a higher oxygenation index (=0.004) and a lower incidence of postoperative pulmonary complications (=0.007).
CONCLUSION: In morbid obesity, sugammadex promotes faster diaphragmatic recovery and improves respiratory outcomes compared with neostigmine and is associated with a lower incidence of postoperative pulmonary complications.